News

Biopharmaceutical company Longeveron will use a $3 million Alzheimer’s Association grant to advance innovative research that uses adult stem cells to target neuroinflammation in people with mild Alzheimer’s disease (AD). Funding is through the organization’s Part the Cloud global research grant program, designed to find promising targets…

Following the approval of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), Samus Therapeutics is launching a Phase 1 trial in the United States to evaluate the safety of its investigational therapy PU-AD, an epichaperome inhibitor, for the treatment of Alzheimer’s…

An online test, called MemTrax, may help screen and predict the progression of cognitive impairment in Alzheimer’s and other disorders, according to a new study using artificial intelligence. The research, “Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification,” was published in…